Clinical Read2026-06-01

Darovasertib with crizotinib - (OptimUM-02)

IDEAYA Biosciences Inc.IDYA
Indication
First line (1L) HLA*A2-negative metastatic uveal melanoma (mUM)
Stage
phase3
Event
Phase 2/3